STOCK TITAN

Design Therapeutics, Inc. Stock Price, News & Analysis

DSGN Nasdaq

Welcome to our dedicated page for Design Therapeutics news (Ticker: DSGN), a resource for investors and traders seeking the latest updates and insights on Design Therapeutics stock.

Design Therapeutics, Inc. (DSGN) is a clinical-stage biopharmaceutical company advancing novel therapies for genetic disorders through its proprietary GeneTAC™ platform. This page serves as the definitive source for official company announcements, research developments, and regulatory updates.

Investors and industry observers will find timely updates on clinical trial progress, partnership announcements, and scientific milestones across DSGN's pipeline targeting Friedreich ataxia, Fuchs endothelial dystrophy, and other degenerative genetic conditions. Our curated news collection provides:

• Clinical development updates
• Regulatory filings and approvals
• Research collaboration announcements
• Financial reporting disclosures

Bookmark this page for direct access to verified information about DSGN's innovative approach to gene-targeted therapies. Check regularly for new developments in genomic medicine and therapeutic advancements.

Rhea-AI Summary

Design Therapeutics (NASDAQ: DSGN) announced its Q3 2024 financial results and pipeline updates. The company initiated a Phase 1 trial for FECD with data expected in H1 2025, and plans to start a Phase 1 trial for Friedreich Ataxia in H1 2025. The company reported R&D expenses of $11.9M, G&A expenses of $4.4M, and a net loss of $13.0M for Q3 2024. With $254.1M in cash and securities, Design Therapeutics expects to fund operations into 2029, supporting up to four potential clinical proof-of-concept data sets. The company is also advancing preclinical programs in Huntington's Disease and Myotonic Dystrophy Type-1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
-
Rhea-AI Summary

Design Therapeutics (Nasdaq: DSGN), a biotech company focused on developing treatments for serious degenerative genetic diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, September 19, 2024, at 12:45 p.m. ET in New York.

Investors and interested parties can access a live webcast of the fireside chat through a provided link and on the company's website at www.designtx.com in the investors section. The webcast will remain archived for at least 30 days after the presentation, allowing for later viewing.

This participation in a major healthcare conference highlights Design Therapeutics' commitment to engaging with the investment community and sharing updates on their progress in developing innovative treatments for genetic diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.69%
Tags
conferences
-
Rhea-AI Summary

Design Therapeutics (Nasdaq: DSGN) reported its Q2 2024 financial results and provided updates on its GeneTAC™ portfolio. Key highlights include:

1. Friedreich Ataxia (FA) program DT-216P2 on track for patient trials in 2025.
2. Fuchs Endothelial Corneal Dystrophy (FECD) candidate DT-168 advancing to Phase 1 in 2024.
3. Ongoing research in Myotonic Dystrophy Type-1 (DM1) and Huntington's Disease (HD).
4. Q2 2024 financial results: R&D expenses $10.5M, G&A expenses $4.5M, net loss $11.8M.
5. Strong cash position of $261.0M, expected to fund operations into 2029.

The company aims to generate clinical proof-of-concept data across its portfolio, addressing serious degenerative genetic diseases with novel small molecule therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
Rhea-AI Summary

Design Therapeutics announced their first quarter 2024 financial results and upcoming program milestones. They are advancing a new drug product for Friedreich Ataxia and Fuchs Endothelial Corneal Dystrophy towards clinical trials. The company is progressing pipeline programs for Huntington’s Disease and Myotonic Dystrophy Type-1. Design Therapeutics also highlighted their cash and securities of $270.7 million, supporting multi-year operating runway.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
-
Rhea-AI Summary

Design Therapeutics, a biotechnology company focused on treating degenerative genetic diseases, will be participating in the 2024 RBC Capital Markets Global Healthcare Conference. The company's management will be involved in a fireside chat scheduled for May 15, 2024, at 11:30 a.m. ET in New York. The event will be live webcasted and archived for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.49%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.97%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.71%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-70.46%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-70.46%
Tags

FAQ

What is the current stock price of Design Therapeutics (DSGN)?

The current stock price of Design Therapeutics (DSGN) is $3.68 as of July 2, 2025.

What is the market cap of Design Therapeutics (DSGN)?

The market cap of Design Therapeutics (DSGN) is approximately 224.2M.
Design Therapeutics, Inc.

Nasdaq:DSGN

DSGN Rankings

DSGN Stock Data

224.24M
34.33M
36.36%
59.34%
5.67%
Biotechnology
Pharmaceutical Preparations
Link
United States
CARLSBAD